Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Unknown 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 196OTHER 174NIH 11NETWORK 9UNKNOWN 4OTHER_GOV 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Tumor-Agnostic 1

Conditions

Breast Neoplasms 3Estrogen Receptor Positive Breast Cancer 1

Interventions

Tamoxifen 10Capecitabine 10Trastuzumab 9Docetaxel 9pyrotinib 7Exercise 7Control Groups 7Vinorelbine 6Paclitaxel 6Letrozole 6Gemcitabine 6Cyclophosphamide 6Carboplatin 6exemestane 5Indocyanine Green 5Anastrozole 5pertuzumab 4dalpiciclib 4Injections 4Fulvestrant 4Doxorubicin 4Surgical Procedures, Operative 3Standard of Care 3Radiotherapy 3Radiation 3Mammography 3Epirubicin 3Drug Therapy 3Cisplatin 3Bevacizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER_GOV × Fulvestrant × Breast × Clear all
NCT01992952 2025-11-26

FAKTION

Velindre NHS Trust

Phase 1/2 Active not recruiting
149 enrolled
Breast

Estrogen Receptor Positive Breast Cancer

NCT05176080 2024-12-17

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Henan Cancer Hospital

Phase 1/2 Terminated
46 enrolled
Breast

Breast Neoplasms

NCT05328440 2023-09-25

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled
Breast

Breast Neoplasms

NCT03024580 2019-08-15

MEGA

Instituto Nacional de Cancer, Brazil

Phase 2 Unknown
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡